Ajanta Pharma
BSE: 532331 | NSE: AJANTPHARM | ISIN: INE031B01049 | SECTOR: Biotechnology & DrugsOpen
1,314.40High
1,330.30Low
1,302.75Prev Close
1,312.30P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
167.34BVolume
1.01KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
-Ask
-
Promoter Pledge Holding - 7.68%
| Promoter Name | No of Shares | Percentage |
|---|---|---|
| Ravi P Agrawal, trustee Ravi Agrawal Trust | 65,46,020 | 5.19% |
| Aayush M Agrawal, trustee Aayush Agrawal Trust | 31,18,207 | 2.47% |
Company Description
- Biotechnology & Drugs
BSE
532331NSE
AJANTPHARMISIN
INE031B01049
Ajanta Pharma Limited is an India-based company, which is primarily involved in development, manufacturing and marketing of specialty pharmaceutical finished dosages. The Company’s marketing network operates in domestic and international markets. The Company produces a comprehensive range of specialty products targeting different therapeutic segments for the treatment of patients, customized to each market it is present in. The branded generics business is spread in India and approximately 30 emerging countries across Africa, South-East Asia, West Asia, and The Commonwealth of Independent States (CIS). It has product portfolio includes complex technology products. The Company has also made substantial investments in its research and development (R&D) facilities.
Company Officers
Madhusudan Agrawal
Executive Vice Chairman of the BoardArvind Agrawal
Chief Financial OfficerGaurang Shah
Compliance Officer, Vice President - Legal, Company SecretaryRajesh Agrawal
Joint Managing Director, Executive DirectorYogesh Agrawal
Managing Director, Executive Director